FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Clifford Hudis

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sarat Chandarlapaty; Dilip Giri; Adriana Heguy; Clifford Hudis; Shanu Modi; Monica Morrow; Larry Norton; Sujata Patil; Neal Rosen; Rita A Sakr; Tari A King
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer.
K J Ruddy; E P Winer; B N Pitcher; L E Archer; H J Cohen; Clifford Hudis; Hyman Muss; Ann H Partridge
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Lawrence N Shulman; Eric P Winer; James N Atkins; Heather P Becker; Donald A Berry; Constance Cirrincione; Gretchen Kimmick; Silvana Martino; Erica Mayer; Hyman Muss; Larry Norton; Ruth O'Regan; Edith A Perez; Charles J Schneider; Clifford Hudis
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Clifford Hudis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sarat Chandarlapaty; Dilip Giri; Adriana Heguy; Clifford Hudis; Shanu Modi; Monica Morrow; Larry Norton; Sujata Patil; Neal Rosen; Rita A Sakr; Tari A King
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(24):6784-91.
2012: K J Ruddy; E P Winer; B N Pitcher; L E Archer; H J Cohen; Clifford Hudis; Hyman Muss; Ann H Partridge
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(12):3075-81.
2012: Lawrence N Shulman; Eric P Winer; James N Atkins; Heather P Becker; Donald A Berry; Constance Cirrincione; Gretchen Kimmick; Silvana Martino; Erica Mayer; Hyman Muss; Larry Norton; Ruth O'Regan; Edith A Perez; Charles J Schneider; Clifford Hudis
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(33):4071-6.
2012: Alice Ho; Clifford Hudis; Joanne Chou; Peter G Cordeiro; Joseph Disa; Amanda McLane; Babak Mehrara; Simon Powell; Kimberly J Van Zee; Jean Wright; Zhigang Zhang; Beryl Mc Cormick
Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation.
Cancer 2012;118(9):2552-9.
2012: Jeremy Setton; Lee Tan; Jeffrey Catalano; Hiram Cody; Clifford Hudis; Beryl Mc Cormick; Monica Morrow; Simon Powell; Alice Ho
Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
Cancer 2012;118(8):1994-2003.
2012: S M Lichtman; Hyman Muss; Andrew D Seidman; E Winer; C T Cirrincione; H J Cohen; Clifford Hudis; Arti Hurria
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(3):632-8.
2011: Abenaa Brewster; Stephen B Edge; C Etzel; Clifford Hudis; M E Hughes; Rebecca A Ottesen; Jane C Weeks; J Wilson; Y Wong; R Zhou; D W Blayney; Richard L Theriault
The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers.
Breast cancer research and treatment 2011;130(3):897-904.
2011: Monica Fornier; Teresa A Gilewski; A Abbruzzi; Jacqueline F Bromberg; J Chang; Gabriella D'Andrea-Carlino; Chau Dang; Maura Dickler; S Modi; P G Morris; Larry Norton; Andrew D Seidman; Nancy T Sklarin; Clifford Hudis
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2575-81.
2011: Ayca Gucalp; Clifford Hudis; Joan Massague; Larry Norton; Sujata Patil; Christine Pellegrino; Jean Santamauro; Joseph A Sparano; Maria Theodoulou-Haber; Alyson Abbruzzi; Jackie Bromberg; James Caravelli; Chau Dang; Tiffany A Traina
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Clinical breast cancer 2011;11(5):306-11.
2011: E Comen; M Davids; Clifford Hudis; Tomas Kirchhoff; Kenneth Offit; Mark Robson
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Breast cancer research and treatment 2011;129(1):185-90.
2011: E Comen; L Balistreri; Mithat Gonen; A Dutra-Clarke; M Fazio; J Vijai; Zsofia Kinga Stadler; Noah D Kauff; Tomas Kirchhoff; Clifford Hudis; Kenneth Offit; Mark Robson
Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women.
Breast cancer research and treatment 2011;127(2):479-87.
2011: Alice B Kornblith; Lan Lan; Laura Archer; Ann Partridge; Gretchen Kimmick; Clifford Hudis; Eric Winer; Rebecca Casey; Samantha Bennett; Harvey Jay Cohen; Hyman B Muss
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(8):1022-8.
2011: Shari B Goldfarb; Clifford Hudis; Maura Dickler
Bevacizumab in metastatic breast cancer: when may it be used?
Therapeutic advances in medical oncology 2011;3(2):85-93.
2011: Maurizio Scaltriti; Pieter J Eichhorn; Javier Cortés; Ludmila Prudkin; Claudia Aura; José Jiménez; Sarat Chandarlapaty; Violeta Serra; Aleix Prat; Yasir H Ibrahim; Marta Guzmán; Magui Gili; Olga Rodríguez; Sonia Rodríguez; José Pérez; Simon R Green; Sabine Mai; Neal Rosen; Clifford Hudis; José Baselga
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(9):3761-6.
2011: Patrick G Morris; Clifford Hudis; Jorge Carrasquillo; Steven Larson; Ravinder K Grewal; Catherine Van Poznak
Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2011;69(1):114-9.
2010: Pamela Drullinsky; Steven M Sugarman; Monica N Fornier; Gabriella D'Andrea-Carlino; Teresa Gilewski; Diana Lake; Tiffany Traina; Carolyn Wasserheit-Lieblich; Nancy Sklarin; Deena Atieh-Graham; Nancy Mills; Tiffany Troso-Sandoval; Andrew D Seidman; Jeffrey Yuan; Hamangi Patel; Sujata Patil; Larry Norton; Clifford Hudis
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Clinical breast cancer 2010;10(6):440-4.
2010: Patrick G Morris; Clifford Hudis
Optimizing dose-dense regimens for early-stage breast cancer.
Nature reviews. Clinical oncology 2010;7(12):678-9.
2010: Conleth G Murphy; Joseph B Walsh; Clifford Hudis; Diana Lake; Maria Theodoulou-Haber
Cystoid macular edema secondary to nab-paclitaxel therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):e684-7.
2010: Clifford Hudis; Tiffany A Traina; Larry Norton
Capecitabine dosing is not yet optimized for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2291; author reply 2291-2.
2010: Robert W Carlson; D Craig Allred; Benjamin O Anderson; Harold J Burstein; W Bradford Carter; Stephen B Edge; John K Erban; William B Farrar; Andres Forero; Sharon Hermes Giordano; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford Hudis; Britt-Marie Ljung; P Kelly Marcom; Ingrid A Mayer; Beryl Mc Cormick; Lori J Pierce; Elizabeth C Reed; Mary Lou Smith; George Somlo; Neal S Topham; John H Ward; Eric P Winer; Antonio C Wolff
Breast cancer: noninvasive and special situations.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(10):1182-207.
2010: Mariana Chavez-Macgregor; Jennifer Litton; Huiqin Chen; Sharon H Giordano; Clifford Hudis; Antonio C Wolff; Vicente Valero; Gabriel N Hortobagyi; Melissa L Bondy; Ana M Gonzalez-Angulo
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
Cancer 2010;116(17):4168-77.
2010: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; MaryFran Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(23):3784-96.
2010: Alison K Conlin; Andrew D Seidman; Ariadne M Bach; Diana Lake; Maura Dickler; Gabriella D'Andrea-Carlino; Tiffany A Traina; Michael Danso; Adam M Brufsky; Mansoor Saleh; Alicia Clawson; Clifford Hudis
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2010;10(4):281-7.
2010: Patrick G Morris; Clifford Hudis
Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(21):3407-10.
2010: Heather L McArthur; Clifford Hudis
Chemotherapy: Neoadjuvant trial design: time for a brave new world?
Nature reviews. Clinical oncology 2010;7(7):359-60.
2010: Patrick G Morris; Colleen Lynch; John N Feeney; Sujata M Patil; Jane Howard; Steven M Larson; Maura Dickler; Clifford Hudis; Maxine Jochelson; Heather L McArthur
Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3154-9.
2010: Jeanne S Mandelblatt; Vanessa B Sheppard; Arti Hurria; Gretchen Kimmick; Claudine Isaacs; Kathryn L Taylor; Alice B Kornblith; Anne-Michelle Noone; Gheorghe Luta; Michelle Tallarico; William T Barry; Lisa Hunegs; Robin Zon; Michael Naughton; Eric Winer; Clifford Hudis; Stephen B Edge; Harvey Jay Cohen; Hyman Muss
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3146-53.
2010: Chau Dang; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Patrick Morris; Alyson Abbruzzi; Carol Chen; Richard M Steingart; Sujata M Patil; Larry Norton; Eric Winer; Clifford Hudis
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):2982-8.
2010: Patrick G Morris; Heather L McArthur; Clifford Hudis; Larry Norton
Dose-dense chemotherapy for breast cancer: what does the future hold?
Future oncology (London, England) 2010;6(6):951-65.
2010: Ann H Partridge; Laura Archer; Alice B Kornblith; Julie R Gralow; Debjani Grenier; Edith Perez; Antonio C Wolff; Xiaofei Wang; Helen Kastrissios; Donald Berry; Clifford Hudis; Eric Winer; Hyman Muss
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2418-22.
2010: Lawrence Koutcher; Ase Ballangrud; Peter G Cordeiro; Beryl Mc Cormick; Margie Hunt; Kimberly Van Zee; Clifford Hudis; Kathryn Beal
Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010;94(3):319-23.
2010: Patrick G Morris; Catherine Van Poznak; Shanu Modi; Alex F Mak; Sujata M Patil; Steven M Larson; Clifford Hudis; Chaitanya Divgi; Ravinder K Grewal
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Clinical breast cancer 2010;10(1):33-9.
2010: Tiffany A Traina; Hope S Rugo; James Caravelli; Sujata M Patil; Benjamin Yeh; Michele E Melisko; John W Park; Stephanie Geneus; Matthew Paulson; Jill Grothusen; Andrew D Seidman; Monica Fornier; Diana E Lake; Chau Dang; Mark Robson; Maria Theodoulou-Haber; Carlos D Flombaum; Larry Norton; Clifford Hudis; Maura Dickler
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):628-33.
2010: Sarat Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; Clifford Hudis; Larry Norton; David B Solit; Joaquín Arribas; José Baselga; Neal Rosen
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Oncogene 2010;29(3):325-34.
2010: Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford Hudis
Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.
The oncologist 2010;15(11):1164-8.
2010: Clifford Hudis
From the guest editor: Triple-negative breast cancer.
Cancer journal (Sudbury, Mass.) 2010;16(1):10-1.
2010: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter M Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
The lancet oncology 2010;11(1):55-65.
2009: Patrick G Morris; Maura Dickler; Heather L McArthur; Tiffany A Traina; Steven Sugarman; Nancy Lin; Beverly Moy; Steven Come; Laura Godfrey; Benjamin Nulsen; Carol Chen; Richard M Steingart; Hope S Rugo; Larry Norton; Eric Winer; Clifford Hudis; Chau Dang
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6117-23.
2009: Heather L McArthur; Clifford Hudis
Trastuzumab: a picky partner?
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(20):6311-3.
2009: Yunfeng Cui; Yongqiang Tan; Binsheng Zhao; Laura Liberman; Rakesh Parbhu; Jennifer Kaplan; Maria Theodoulou-Haber; Clifford Hudis; Lawrence H Schwartz
Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed.
Medical physics 2009;36(10):4359-69.
2009: Patrick G Morris; Clifford Hudis
Personalizing therapy for metastatic breast cancer.
Expert review of anticancer therapy 2009;9(9):1223-6.
2009: Tomas Kirchhoff; Zhang-qun Chen; Bert Gold; Prodipto Pal; Mia M. Gaudet; Kristi Kosarin; Douglas A Levine; Peter Gregersen; Sara Spencer; Megan Harlan; Mark Robson; Robert J. Klein; Clifford Hudis; Larry Norton; Michael Dean; Kenneth Offit
The 6q22.33 locus and breast cancer susceptibility.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(9):2468-75.
2009: Lyndsay N Harris; Gloria Broadwater; Maysa Abu-Khalaf; David Cowan; Ann D Thor; Daniel R Budman; Constance T Cirrincione; Donald A Berry; Eric P Winer; Clifford Hudis; Daniel F Hayes; Paula Friedman; Matthew Ellis; Lynn Dressler
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3430-6.
2009: Xiang H-F Zhang; Qiongqing Wang; William Gerald; Clifford Hudis; Larry Norton; Marcel Smid; John A Foekens; Joan Massagué
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Cancer cell 2009;16(1):67-78.
2009: Steven Sugarman; Carolyn Wasserheit; Elizabeth Hodgman; Maryellen Coglianese; Anne D'Alassandro; Monica Fornier; Monica Fournier; Tiffany Troso-Sandoval; Gabriella D'Andrea-Carlino; P Drullinsky; Diana E Lake; Roshini George; Nancy Mills; Mary Ellen Moynahan; Joyce Smith; Katherine S Panageas; Larry Norton; Clifford Hudis
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Breast cancer research and treatment 2009;115(3):609-12.
2009: Hyman Muss; Donald A Berry; Constance Cirrincione; Maria Theodoulou-Haber; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford Hudis; Eric P Winer
Adjuvant chemotherapy in older women with early-stage breast cancer.
The New England journal of medicine 2009;360(20):2055-65.
2009: Maria Theodoulou-Haber; Gerald Batist; Susana Campos; Eric P Winer; Lauri Welles; Clifford Hudis
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
Clinical breast cancer 2009;9(2):101-7.
2009: Liying Zhang; Ruben Bacares; Sherry Boyar; Clifford Hudis; Khedoudja Nafa; Kenneth Offit
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Mutation research 2009;663(1-2):84-9.
2009: Patrick G Morris; Heather L McArthur; Clifford Hudis
Therapeutic options for metastatic breast cancer.
Expert opinion on pharmacotherapy 2009;10(6):967-81.
2009: Ana M Gonzalez-Angulo; Katherine Stemke-Hale; Shana L Palla; Mark Carey; Roshan Agarwal; Funda Meric-Berstam; Tiffany A Traina; Clifford Hudis; Gabriel N Hortobagyi; William L Gerald; Gordon B Mills; Bryan T. J. Hennessy
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2472-8.
2009: Robert W Carlson; D Craig Allred; Benjamin O Anderson; Harold J Burstein; W Bradford Carter; Stephen B Edge; John K Erban; William B Farrar; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford Hudis; Mohammad Jahanzeb; Krystyna Kiel; Britt-Marie Ljung; Paul Kelly Marcom; Ingrid A Mayer; Beryl Mc Cormick; Lisle M Nabell; Lori J Pierce; Elizabeth C Reed; Mary Lou Smith; George Somlo; Richard L Theriault; Neal S Topham; John H Ward; Eric P Winer; Antonio C Wolff
Breast cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(2):122-92.
2009: G G Kimmick; C Cirrincione; D B Duggan; Kapil N Bhalla; N Robert; D Berry; Larry Norton; S Lemke; I C Henderson; Clifford Hudis; E Winer
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Breast cancer research and treatment 2009;113(3):479-90.
2008: Kotha Subbaramaiah; Robert Benezra; Clifford Hudis; Andrew J Dannenberg
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.
The Journal of biological chemistry 2008;283(49):33955-68.
2008: Maura Dickler; Hope S Rugo; Carey A Eberle; Edi Brogi; James Caravelli; Katherine S Panageas; Jeff Boyd; Benjamin Yeh; Diana E Lake; Chau Dang; Teresa A Gilewski; Jacqueline F Bromberg; Andrew D Seidman; Gabriella D'Andrea-Carlino; Mark M Moasser; Michele Melisko; John W Park; Janet Dancey; Larry Norton; Clifford Hudis
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7878-83.
2008: Conleth Murphy; Clifford Hudis; Maura Dickler
Aromatase inhibitors and arthralgia: a growing pain?
Oncology (Williston Park, N.Y.) 2008;22(12):1424, 1426.
2008: Chau Dang; Gabriella D'Andrea-Carlino; Diana E Lake; Steve Sugarman; Monica Fornier; Mary Ellen Moynahan; Teresa A Gilewski; Arti Hurria; Nancy Mills; Tiffany Troso-Sandoval; Roshini George; Mark Robson; Maura Dickler; Karen Smith; Katherine S Panageas; Larry Norton; Clifford Hudis
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Clinical breast cancer 2008;8(5):418-24.
2008: M F Barginear; Catherine Van Poznak; Neal Rosen; Shanu Modi; Clifford Hudis; D R Budman
The heat shock protein 90 chaperone complex: an evolving therapeutic target.
Current cancer drug targets 2008;8(6):522-32.
2008: Tiffany A Traina; Italo POggesi; Mark Robson; A Asnis; B A Duncan; Alexandra S Heerdt; Chau Dang; Diana E Lake; Mark M Moasser; Katherine S Panageas; Patrick I Borgen; Larry Norton; Clifford Hudis; Maura Dickler
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Breast cancer research and treatment 2008;111(2):377-88.
2008: Chau Dang; Larry Norton; Clifford Hudis
Dose-dense chemotherapy with trastuzumab is an appropriate option.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3655-6; author reply 3656.
2008: Clifford Hudis; Chau Dang
The taxane limbo: how low can we go?
Journal of the National Cancer Institute 2008;100(11):761-3.
2008: Blase N Polite; Constance Cirrincione; Gini F Fleming; Donald A Berry; Andrew D Seidman; Hyman Muss; Larry Norton; Charles Shapiro; Kamal Bakri; Paul Kelly Marcom; Diana Lake; Joel H Schwartz; Clifford Hudis; Eric P Winer
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2659-65.
2008: Minetta C Liu; George D Demetri; Donald A Berry; Larry Norton; Gloria Broadwater; Nicholas J Robert; David Duggan; Daniel F Hayes; I Craig Henderson; Alan Lyss; Judith Hopkins; Peter A Kaufman; Paul Kelly Marcom; Jerry Younger; Nancy U Lin; Katherine Tkaczuk; Eric P Winer; Clifford Hudis
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Cancer treatment reviews 2008;34(3):223-30.
2008: Tiffany A Traina; Maria Theodoulou-Haber; Kimberly Feigin; Sujata M Patil; K Lee Tan; Charles Edwards; Ute Dugan; Larry Norton; Clifford Hudis
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1797-802.
2008: Lee K Tan; Dilip D Giri; Amanda J Hummer; Katherine S Panageas; Edi Brogi; Larry Norton; Clifford Hudis; Patrick I Borgen; Hiram S Cody
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1803-9.
2008: Margaret C Kirk; Clifford Hudis
Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer.
Clinical breast cancer 2008;8(2):155-61.
2008: Andrew D Seidman; Donald Berry; Constance Cirrincione; Lyndsay Harris; Hyman Muss; Paul Kelly Marcom; Grandella Gipson; Harold J Burstein; Diana E Lake; Charles L Shapiro; Peter Ungaro; Larry Norton; Eric Winer; Clifford Hudis
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1642-9.
2008: Chau Dang; Monica Fornier; Steven Sugarman; Tiffany Troso-Sandoval; Diana E Lake; Gabriella D'Andrea-Carlino; Andrew D Seidman; Nancy T Sklarin; Maura Dickler; Violante E Currie; Teresa A Gilewski; Mary Ellen Moynahan; P Drullinsky; Mark Robson; Carolyn Wasserheit-Leiblich; Nancy Mills; Richard M Steingart; Katherine S Panageas; Larry Norton; Clifford Hudis
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1216-22.
2008: Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1331-7.
2008: Edith A Perez; Vera J Suman; Nancy E Davidson; George W Sledge; Peter A Kaufman; Clifford Hudis; Silvana Martino; Julie R Gralow; Shaker R Dakhil; James N Ingle; Eric P Winer; Karen Gelmon; Bernard J Gersh; Allan S Jaffe; Richard J Rodeheffer
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1231-8.
2008: Kotha Subbaramaiah; Clifford Hudis; Sung-Hee Chang; Timothy Hla; Andrew J Dannenberg
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
The Journal of biological chemistry 2008;283(6):3433-44.
2008: Heather L McArthur; Clifford Hudis
Advances in adjuvant chemotherapy of early stage breast cancer.
Cancer treatment and research 2008;141():37-53.
2008: Jean Wright; Peter G Cordeiro; Leah Ben-Porat; Kimberly Van Zee; Clifford Hudis; Kathryn Beal; Beryl Mc Cormick
Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.
International journal of radiation oncology, biology, physics 2008;70(1):43-50.
2007: Clifford Hudis; Shanu Modi
Preoperative chemotherapy for breast cancer: miracle or mirage?
JAMA : the journal of the American Medical Association 2007;298(22):2665-7.
2007: Gary Deng; Andrew J Vickers; Simon Yeung; Gabriella D'Andrea-Carlino; Han Xiao; Alexandra S Heerdt; Steven Sugarman; Tiffany Troso-Sandoval; Andrew D Seidman; Clifford Hudis; Barrie R Cassileth
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5584-90.
2007: Heather L McArthur; Clifford Hudis
Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.
Clinical breast cancer 2007;8 Suppl 1():S6-S10.
2007: Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford Hudis
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Clifford Hudis; Heather L McArthur; Chau Dang
Current status of the taxanes as adjuvant therapy for breast cancer.
Breast (Edinburgh, Scotland) 2007;16 Suppl 2():S132-5.
2007: Michael L Krychman; Carla J Stelling; Jeanne Carter; Clifford Hudis
A case series of androgen use in breast cancer survivors with sexual dysfunction.
The journal of sexual medicine 2007;4(6):1769-74.
2007: Daniel F Hayes; Ann D Thor; Lynn Dressler; Donald Weaver; Susan M Edgerton; David Cowan; Gloria Broadwater; Lori J Goldstein; Silvana Martino; James N Ingle; I Craig Henderson; Larry Norton; Eric P Winer; Clifford Hudis; Matthew J Ellis; Donald A Berry
HER2 and response to paclitaxel in node-positive breast cancer.
The New England journal of medicine 2007;357(15):1496-506.
2007: Monica Fornier; Dana Elizabeth Rathkopf; Manish A Shah; Sujata M Patil; Eileen O'Reilly; Archie N Tse; Clifford Hudis; Robert Lefkowitz; David P Kelsen; Gary K Schwartz
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5841-6.
2007: Hyman Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford Hudis
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3699-704.
2007: Heather L McArthur; Clifford Hudis
Has first-line therapy had an impact on general outcome in metastatic breast cancer?
Future oncology (London, England) 2007;3(4):411-8.
2007: Karen Lisa Smith; Muriel Adank; Noah D Kauff; Kelly J Lafaro; Jeff Boyd; Johanna B Lee; Clifford Hudis; Kenneth Offit; Mark Robson
BRCA mutations in women with ductal carcinoma in situ.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4306-10.
2007: Clifford Hudis
Trastuzumab--mechanism of action and use in clinical practice.
The New England journal of medicine 2007;357(1):39-51.
2007: Clifford Hudis; William E Barlow; Joseph P Costantino; Robert J Gray; Kathleen I Pritchard; Judith-Anne W Chapman; Joseph A Sparano; Sally Hunsberger; Rebecca A Enos; Richard D Gelber; Jo Anne Zujewski
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2127-32.
2007: Teresa A Gilewski; Govind Ragupathi; Maura Dickler; Shemeeakah Powell; Sonal Bhuta; Katherine S Panageas; R Rao Koganty; Jeannette Chin-Eng; Clifford Hudis; Larry Norton; Alan N Houghton; Philip O Livingston
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2977-85.
2007: Heather L McArthur; Clifford Hudis
Breast cancer chemotherapy.
Cancer journal (Sudbury, Mass.) 2007;13(3):141-7.
2007: Halle C F Moore; Stephanie J Green; Julie R Gralow; Scott I Bearman; Danika Lew; William E Barlow; Clifford Hudis; Antonio C Wolff; James N Ingle; Helen K Chew; Anthony D Elias; Robert B Livingston; Silvana Martino
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1677-82.
2007: Heather L McArthur; Clifford Hudis
Adjuvant chemotherapy for early-stage breast cancer.
Hematology/oncology clinics of North America 2007;21(2):207-22.
2007: Robert W Carlson; Benjamin O Anderson; Harold J Burstein; W Bradford Carter; Stephen B Edge; William B Farrar; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford Hudis; Mohammad Jahanzeb; Britt-Marie Ljung; Krystyna Kiel; Lawrence Marks; Beryl Mc Cormick; Lisle M Nabell; Lori J Pierce; Elizabeth C Reed; Samuel Michael Silver; Mary Lou Smith; George Somlo; Richard L Theriault; John H Ward; Eric P Winer; Antonio C Wolff
Invasive breast cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(3):246-312.
2007: Arti Hurria; Arash Naeim; Elena B Elkin; Sewanti Limaye; Anjali Grover; Clifford Hudis; Carol Pearce; Mark Robson
Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Critical reviews in oncology/hematology 2007;61(3):255-60.
2007: Monica Fornier; Andrew D Seidman; Diana E Lake; Gabriella D'Andrea-Carlino; Jacqueline F Bromberg; Mark Robson; Catherine Van Poznak; Katherine S Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):223-7.
2006: Rowan T Chlebowski; George L Blackburn; Cynthia A Thomson; Daniel W Nixon; Alice Shapiro; M Katherine Hoy; Marc T Goodman; Armando E Giuliano; Njeri Karanja; Philomena McAndrew; Clifford Hudis; John Butler; Douglas Merkel; Alan Kristal; Bette Caan; Richard Michaelson; Vincent Vinciguerra; Salvatore Del Prete; Marion Winkler; Rayna Hall; Michael Steven Simon; Barbara L Winters; Robert M Elashoff
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
Journal of the National Cancer Institute 2006;98(24):1767-76.
2006: Mercedes Rincon; Gloria Broadwater; Lyndsay Harris; Abigail Crocker; Donald Weaver; Lynn Dressler; Donald Berry; Linda Sutton; Richard Michaelson; Michael Messino; Jeffrey Kirshner; Gini Fleming; Eric P Winer; Clifford Hudis; Stacy Appel; Larry Norton; Hyman Muss
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Breast cancer research and treatment 2006;100(3):301-8.
2006: Robert W Carlson; Clifford Hudis; Kathy I Pritchard
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):971-9.
2006: Arti Hurria; Mark T Fleming; Sharyn D Baker; W Kevin Kelly; Katie Cutchall; Katherine S Panageas; James Caravelli; Henry Yeung; Mark G Kris; Jorge Gomez; Vincent A Miller; Gabriella D'Andrea-Carlino; Howard I Scher; Larry Norton; Clifford Hudis
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Shanu Modi; Gabriella D'Andrea-Carlino; Larry Norton; Tzy-Jyun Yao; James Caravelli; Peter P Rosen; Clifford Hudis; Andrew D Seidman
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer 2006;7(3):270-7.
2006: Arti Hurria; Shari Goldfarb; Carol Rosen; Jimmie C Holland; Enid Zuckerman; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea-Carlino; Mark M Moasser; Chau Dang; Catherine Van Poznak; Mark Robson; Violante E Currie; Maria Theodoulou-Haber; Larry Norton; Clifford Hudis
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Breast cancer research and treatment 2006;98(3):343-8.
2006: Arti Hurria; Anju Hurria; Enid Zuckerman; Katherine S Panageas; Monica Fornier; Gabriella D'Andrea-Carlino; Chau Dang; Mark M Moasser; Mark Robson; Andrew D Seidman; Violante E Currie; Catherine Van Poznak; Maria Theodoulou-Haber; Mark S Lachs; Clifford Hudis
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
Journal of the American Geriatrics Society 2006;54(7):1119-24.
2006: Robert W Carlson; Susan J Moench; M Elizabeth H Hammond; Edith A Perez; Harold J Burstein; D Craig Allred; Charles L Vogel; Lori J Goldstein; George Somlo; William J Gradishar; Clifford Hudis; Mohammad Jahanzeb; Azadeh Stark; Antonio C Wolff; Michael F Press; Eric P Winer; Soonmyung Paik; Britt-Marie Ljung
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 3():S1-22; quiz S23-4.
2006: Chau Dang; Clifford Hudis
Can granulocyte-colony stimulating factor worsen anemia?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):2985-6.
2006: A S Doane; M Danso; P Lal; M Donaton; Liying Zhang; Clifford Hudis; William L Gerald
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
Oncogene 2006;25(28):3994-4008.
2006: Harold J Burstein; Erica L Mayer; Ann H Patridge; Holly O'Kane; Georgia Litsas; Steven E Come; Clifford Hudis; Donald F Goldstein; Hyman Muss; Eric P Winter; Judy E Garber
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
Clinical breast cancer 2006;7(2):158-61.
2006: Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea-Carlino; Mark M Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie C Holland
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
Journal of the American Geriatrics Society 2006;54(6):925-31.
2006: Clifford Hudis; Eric P Winer
Cancer and leukemia group B breast committee: decades of progress and plans for the future.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3576s-80s.
2006: Kotha Subbaramaiah; Louise R Howe; Elisa Rush Port; Edi Brogi; Jack Fishman; Catherine H Liu; Timothy Hla; Clifford Hudis; Andrew J Dannenberg
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Cancer research 2006;66(10):5504-11.
2006: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman Muss; Larry Norton; Clifford Hudis; Eric P Winer
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA : the journal of the American Medical Association 2006;295(14):1658-67.
2006: Chau Dang; Clifford Hudis
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Clinical breast cancer 2006;7(1):51-8.
2006: Robert W Carlson; Elizabeth Brown; Harold J Burstein; William J Gradishar; Clifford Hudis; Charles L Loprinzi; Eleftherios Paul Mamounas; Edith A Perez; Kathleen Pritchard; Peter M Ravdin; Abram Recht; George Somlo; Richard L Theriault; Eric P Winer; Antonio C Wolff
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 1():S1-26.
2006: Clifford Hudis
Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer.
Nature clinical practice. Oncology 2006;3(1):12-3.
2006: Catherine Van Poznak; Simon Cross; M Saggese; Clifford Hudis; Katherine S Panageas; Larry Norton; Robert E Coleman; Ingunn Holen
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Journal of clinical pathology 2006;59(1):56-63.
2005: Gabriel N Hortobagyi; Jaime De la Garza-Salazar; Kathleen Pritchard; Dino Amadori; Renate Haidinger; Clifford Hudis; Hussein M Khaled; Mei-Ching Liu; Miguel Martin; Moise Namer; Joyce A O'Shaughnessy; Zhen Zhou Shen; Kathy S Albain
The global breast cancer burden: variations in epidemiology and survival.
Clinical breast cancer 2005;6(5):391-401.
2005: Clifford Hudis
The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs.
Breast (Edinburgh, Scotland) 2005;14(6):570-5.
2005: Louise R Howe; Sung-Hee Chang; Kelly C Tolle; Rachelle Dillon; Lawrence J T Young; Robert Cardiff; Robert A Newman; Peiying Yang; Howard T Thaler; William J Muller; Clifford Hudis; Anthony M C Brown; Timothy Hla; Kotha Subbaramaiah; Andrew J Dannenberg
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Cancer research 2005;65(21):10113-9.
2005: Arti Hurria; Supriya Gupta; Marjorie Zauderer; Enid Zuckerman; Harvey J Cohen; Hyman Muss; Miriam Rodin; Katherine S Panageas; Jimmie C Holland; Leonard B Saltz; Mark G Kris; Ariela Noy; Jorge Gomez; Ann Jakubowski; Clifford Hudis; Alice B Kornblith
Developing a cancer-specific geriatric assessment: a feasibility study.
Cancer 2005;104(9):1998-2005.
2005: Monica Fornier; Shanu Modi; Katherine S Panageas; Larry Norton; Clifford Hudis
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Cancer 2005;104(8):1575-9.
2005: Elena B Elkin; Clifford Hudis; Colin B Begg; Deborah Schrag
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.
Cancer 2005;104(6):1149-57.
2005: Kathryn Beal; Clifford Hudis; Larry Norton; Raquel Wagman; Beryl Mc Cormick
Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
The breast journal 2005;11(5):317-20.
2005: Clifford Hudis
Testing chemotherapy for breast cancer: timing is everything.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5434-6.
2005: Arti Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Marjorie Zauderer; Jane Howard; Clifford Hudis
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Breast cancer research and treatment 2005;92(2):151-6.
2005: Clifford Hudis; Charles L Vogel; Julie R Gralow; Denise Williams
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Clinical breast cancer 2005;6(2):132-42.
2005: Robert W Carlson; Benjamin O Anderson; Harold J Burstein; Charles E Cox; Stephen B Edge; William B Farrar; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford Hudis; Mohammad Jahanzeb; Britt-Marie Ljung; Lawrence Marks; Beryl Mc Cormick; Lisle M Nabell; Lori J Pierce; Elizabeth C Reed; Samuel Michael Silver; Mary Lou Smith; George Somlo; Richard L Theriault; John H Ward; Eric P Winer; Antonio C Wolff
Breast cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(3):238-89.
2005: Clifford Hudis
Clinical implications of antiangiogenic therapies.
Oncology (Williston Park, N.Y.) 2005;19(4 Suppl 3):26-31.
2005: Shanu Modi; Violante E Currie; Andrew D Seidman; Ariadne M Bach; Katherine S Panageas; Maria Theodoulou-Haber; Mark M Moasser; Gabriella D'Andrea-Carlino; Diana E Lake; Jennifer Choi; Larry Norton; Clifford Hudis
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005;6(1):55-60.
2005: Hyman Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel R Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric P Winer; Harvey Cohen; Judith Wheeler; Larry Norton
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA : the journal of the American Medical Association 2005;293(9):1073-81.
2005: Shanu Modi; Andrew D Seidman; Maura Dickler; Mark M Moasser; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Jennifer H Menell; Katherine S Panageas; Lee K Tan; Larry Norton; Clifford Hudis
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005;90(2):157-63.
2005: Marc Lippman; Chris Benz; Arul M Chinnaiyan; David A Flockhart; Adrian Harris; Clifford Hudis; C Kent Osborne; Michael F Press; James M Rae; George W Sledge; Laura Van't Veer; Max S Wicha
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
Breast cancer research and treatment 2005;90(1):1-3.
2005: Monica Fornier; Andrew D Seidman; Morton K Schwartz; F Ghani; Robert P Thiel; Larry Norton; Clifford Hudis
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):234-9.
2005: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard D Gelber; Stephen B Edge; Julie R Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):619-29.
2005: Shanu Modi; Michael P DiGiovanna; Zhao Lu; Chaya S Moskowitz; Katherine S Panageas; Catherine Van Poznak; Clifford Hudis; Larry Norton; Lee Tan; David F Stern; Darryl L Carter; Andrew D Seidman
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Drugs & aging 2005;22(9):785-91.
2005: Arti Hurria; Kelly Brogan; Katherine S Panageas; Ann Jakubowski; Marjorie Zauderer; Carol Pearce; Larry Norton; Jane Howard; Clifford Hudis
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Drugs & aging 2005;22(8):709-15.
2005: Monica Fornier; Clifford Hudis
Adjuvant chemotherapy for primary breast cancer.
Current oncology reports 2005;7(1):18-22.
2005: Mark Robson; Tiffany Svahn; Beryl Mc Cormick; Patrick I Borgen; Clifford Hudis; Larry Norton; Kenneth Offit
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Cancer 2005;103(1):44-51.
2004: Michael W Kattan; Dilip D Giri; Katherine S Panageas; Amanda J Hummer; Milicent Cranor; Kimberly Van Zee; Clifford Hudis; Larry Norton; Patrick I Borgen; Lee K Tan
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
Cancer 2004;101(11):2509-15.
2004: Debu Tripathy; Andrew D Seidman; Deborah Keefe; Clifford Hudis; Virginia Paton; Grazyna Lieberman
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2004;5(4):293-8.
2004: Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl Mc Cormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman Muss; Eric P Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
The New England journal of medicine 2004;351(10):971-7.
2004: Chau Dang; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Maura Dickler; Andrew D Seidman; Monica Fornier; Mark Robson; Maria Theodoulou-Haber; Diana E Lake; Violante E Currie; Arti Hurria; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5754-61.
2004: Tari A King; Archana Ganaraj; Jane V Fey; Lee K Tan; Clifford Hudis; Larry Norton; Hiram S Cody; Patrick I Borgen
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
Cancer 2004;101(5):926-33.
2004: Chau Dang; Andrew J Dannenberg; Kotha Subbaramaiah; Maura Dickler; Mark M Moasser; Andrew D Seidman; Gabriella D'Andrea-Carlino; Maria Theodoulou-Haber; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4062-7.
2004: Clifford Hudis; Norbert Schmitz
Dose-dense chemotherapy in breast cancer and lymphoma.
Seminars in oncology 2004;31(3 Suppl 8):19-26.
2004: Eric P Winer; Donald A Berry; Susan Woolf; David B Duggan; Alice B Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark Graham II; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2061-8.
2004: Maria Theodoulou-Haber; Clifford Hudis
Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Cancer 2004;100(10):2052-63.
2004: Priti Lal; Paulo A Salazar; Clifford Hudis; Marc Ladanyi; Beiyun Chen
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
American journal of clinical pathology 2004;121(5):631-6.
2004: Clifford Hudis; Chau Dang
Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.
Breast disease 2004;21():3-13.
2004: Heinz Ludwig; Clifford Hudis; Glen Goss; Brian Leyland-Jones
Epoetin alfa: future directions and future research.
The oncologist 2004;9 Suppl 5():70-3.
2004: Clifford Hudis; Simon Van Belle; Jose Chang; Karsten Muenstedt
rHuEPO and treatment outcomes: the clinical experience.
The oncologist 2004;9 Suppl 5():55-69.
2004: Diana E Lake; Clifford Hudis
High-dose chemotherapy in breast cancer.
Drugs 2004;64(17):1851-60.
2004: Mark Robson; Pierre O Chappuis; Jaya M Satagopan; Nora Wong; Jeff Boyd; John R Goffin; Clifford Hudis; David Roberge; Larry Norton; Louis R Bégin; Kenneth Offit; William D Foulkes
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Breast cancer research : BCR 2004;6(1):R8-R17.
2003: Chau Dang; Monica Fornier; Clifford Hudis
Risk models for neutropenia in patients with breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(11 Suppl 11):14-20.
2003: Clifford Hudis
Current status and future directions in breast cancer therapy.
Clinical breast cancer 2003;4 Suppl 2():S70-5.
2003: Arti Hurria; Clifford Hudis
Follow-up care of breast cancer survivors.
Critical reviews in oncology/hematology 2003;48(1):89-99.
2003: Arti Hurria; Denis Leung; Kathleen Trainor; Larry Norton; Clifford Hudis
Screening chest imaging studies are not effective in the follow-up of breast cancer patients.
The Journal of oncology management : the official journal of the American College of Oncology Administrators 2003;12(5):13-5.
2003: Harry Bartelink; Christopher Benz; Don Cleveland; Ronald Dorn; Julie R Gralow; William J Gradishar; Kathleen Grant; Ruth Heimann; Samuel Hellman; Clifford Hudis; Robert S Kerbel; Marc Lippman; John Lung; Mitchell C Posner; Patricia Steeg; Robert Vestal; Ralph R Weichselbaum; Bruce R Zetter
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003.
Breast cancer research and treatment 2003;80(2):139-44.
2003: Eric P Winer; Clifford Hudis; Harold J Burstein; John Bryant; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Richard Gelber; Julie R Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2597-9.
2003: Arti Hurria; Denis Leung; Kathleen Trainor; Patrick I Borgen; Larry Norton; Clifford Hudis
Factors influencing treatment patterns of breast cancer patients age 75 and older.
Critical reviews in oncology/hematology 2003;46(2):121-6.
2003: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David D Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman Muss; Larry Norton
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1431-9.
2003: Noah D Kauff; Edi Brogi; Lauren Scheuer; Dorothy R Pathak; Patrick I Borgen; Clifford Hudis; Kenneth Offit; Mark Robson
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Cancer 2003;97(7):1601-8.
2003: Aman U Buzdar; Joyce A O'Shaughnessy; Daniel J Booser; John Pippen; Stephen E Jones; Pamela N Munster; Patrick Peterson; Allen S Melemed; Eric P Winer; Clifford Hudis
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1007-14.
2002: Clifford Hudis
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Clinical breast cancer 2002;3(5):326-32.
2002: Diana E Lake; Clifford Hudis
Aromatase inhibitors in breast cancer: an update.
Cancer control : journal of the Moffitt Cancer Center 2002;9(6):490-8.
2002: Clifford Hudis
Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine.
Oncology (Williston Park, N.Y.) 2002;16(10 Suppl 12):13-6.
2002: Clifford Hudis
Breast cancer and leukemia: the forest for the trees?
Annals of surgical oncology 2002;9(8):717-8.
2002: Louise R Howe; Kotha Subbaramaiah; Jay Patel; Jaime L Masferrer; Aparna Deora; Clifford Hudis; Howard T Thaler; William J Muller; Baoheng Du; Anthony M C Brown; Andrew J Dannenberg
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Cancer research 2002;62(19):5405-7.
2002: Shanu Modi; Katherine S Panageas; Elaine T Duck; Ariadne M Bach; Nancy Weinstock; James Dougherty; Laura D Cramer; Clifford Hudis; Larry Norton; Andrew D Seidman
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3665-73.
2002: Eric P Winer; Clifford Hudis; Harold J Burstein; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Julie R Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3317-27.
2002: Noah D Kauff; Jaya M Satagopan; Mark Robson; Lauren Scheuer; Martee Hensley; Clifford Hudis; Nathan Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine 2002;346(21):1609-15.
2002: Chau Dang; Charles L Shapiro; Clifford Hudis
Potential role of selective COX-2 inhibitors in cancer management.
Oncology (Williston Park, N.Y.) 2002;16(5 Suppl 4):30-6.
2002: Catherine Van Poznak; Lee Tan; Katherine S Panageas; Crispinita D Arroyo; Clifford Hudis; Larry Norton; Andrew D Seidman
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2319-26.
2002: Andrew D Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Cardiac dysfunction in the trastuzumab clinical trials experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1215-21.
2001: Monica Fornier; Andrew D Seidman; Maria Theodoulou-Haber; Mary Ellen Moynahan; Violante E Currie; Mark M Moasser; Nancy T Sklarin; Teresa A Gilewski; Gabriella D'Andrea-Carlino; R Salvaggio; Katherine S Panageas; Larry Norton; Clifford Hudis
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3934-41.
2001: Raymond B Weiss; G G Gill; Clifford Hudis
An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2771-7.
2001: Andrew D Seidman; Monica Fornier; Francisco J Esteva; Lee Tan; S Kaptain; Ariadne M Bach; Katherine S Panageas; Crispinita D Arroyo; V Valero; Violante E Currie; Teresa A Gilewski; Maria Theodoulou-Haber; Mary Ellen Moynahan; Mark M Moasser; Nancy T Sklarin; Maura Dickler; Gabriella D'Andrea-Carlino; M Cristofanilli; E Rivera; Gabriel N Hortobagyi; Larry Norton; Clifford Hudis
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Catherine Van Poznak; Andrew D Seidman; MM Reidenberg; Mark M Moasser; Nancy T Sklarin; Kimberly Van Zee; Patrick I Borgen; Marc J Gollub; D Bacotti; Tzy-Jyun Yao; R Bloch; M Ligueros; M Sonenberg; Larry Norton; Clifford Hudis
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Breast cancer research and treatment 2001;66(3):239-48.
2001: Pamela N Münster; Aman U Buzdar; Kapil Dhingra; N Enas; L Ni; M Major; Allen S Melemed; Andrew D Seidman; Daniel J Booser; Richard Theriault; Larry Norton; Clifford Hudis
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Teresa A Gilewski; Govind Ragupathi; S Bhuta; Linda J Williams; Cristina Musselli; XF Zhang; William G Bornmann; Maria A Spassova; K P Bencsath; Katherine S Panageas; J Chin; Clifford Hudis; Larry Norton; Alan N Houghton; Philip O Livingston; Samuel J Danishefsky
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(6):3270-5.
2001: Abram Recht; S B Edge; Lawrence J Solin; D S Robinson; A Estabrook; R E Fine; G F Fleming; Silvia C Formenti; Clifford Hudis; J J Kirshner; D A Krause; Robert R Kuske; A S Langer; G W Sledge; Timothy J Whelan; David G Pfister
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1539-69.
2001: J Ajani; David S Ettinger; David P Kelsen; Clifford Hudis; A Kudelka; C Langer; Kenneth J Pienta; H Safran; E E Vokes; W K Yung
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):88-91.
2001: Beryl Mc Cormick; E Strom; P S Craighead; Robert R Kuske; Clifford Hudis; J Ley; L Margolis; B Meyerwitz; Elizabeth A Morris; Jeanne A Petrek; Lori J Pierce; T Pisansky; Rachel Rabinovitch; N Sneige; Frank Vicini; D Unger; Kathryn Winter
Radiation Therapy Oncology Group. Research Plan 2002-2006. Breast Cancer Working Group.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):56-7.
2000: Richard R Barakat; Teresa A Gilewski; Lois Almadrones; Patricia E Saigo; Venkatraman E Seshan; Clifford Hudis; William J Hoskins
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3459-63.
2000: Clifford Hudis
Dose-dense chemotherapy for breast cancer: the story so far.
British journal of cancer 2000;82(12):1897-9.
2000: Teresa A Gilewski; Andrew D Seidman; Larry Norton; Clifford Hudis
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S23-6.
2000: Pamela N Münster; Clifford Hudis
Role of taxanes in adjuvant therapy.
Cancer investigation 2000;18(1):32-8.
2000: J M Donnelly; Alice B Kornblith; Stewart Fleishman; Enid Zuckerman; G Raptis; Clifford Hudis; N Hamilton; D Payne; Mary Jane Massie; Larry Norton; Jimmie C Holland
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.
Psycho-oncology 2000;9(1):44-56.
1999: Mark Robson; D Levin; Mark G Federici; Jaya M Satagopan; F Bogolminy; Alexandra S Heerdt; Patrick I Borgen; Beryl Mc Cormick; Clifford Hudis; Larry Norton; Jeff Boyd; Kenneth Offit
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Journal of the National Cancer Institute 1999;91(24):2112-7.
1999: Laura Liberman; Maureen F Zakowski; S Avery; Clifford Hudis; Elizabeth A Morris; Andrea F Abramson; Linda R LaTrenta; Jill Glassman; D David Dershaw
Complete percutaneous excision of infiltrating carcinoma at stereotactic breast biopsy: how can tumor size be assessed?
AJR. American journal of roentgenology 1999;173(5):1315-22.
1999: José Baselga; Debu Tripathy; John Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I Craig Henderson; Larry Norton
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):78-83.
1999: Clifford Hudis; Monica Fornier; L Riccio; David Lebwohl; John Crown; Teresa A Gilewski; A Surbone; Violante E Currie; Andrew D Seidman; B Reichman; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; Maria Theodoulou-Haber; L Weiselberg; R Salvaggio; Katherine S Panageas; Tzy-Jyun Yao; Larry Norton
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Pamela N Münster; Clifford Hudis
Adjuvant therapy for resectable breast cancer.
Hematology/oncology clinics of North America 1999;13(2):391-413, vi.
1999: Clifford Hudis
The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Seminars in oncology 1999;26(1 Suppl 2):1-5.
1999: Clifford Hudis; Pamela N Münster
High-dose therapy for breast cancer.
Seminars in oncology 1999;26(1):35-47.
1999: Gabriella D'Andrea-Carlino; DW Fennelly; Larry Norton; José Baselga; Teresa A Gilewski; Clifford Hudis; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; Maria Theodoulou-Haber; M A Templeton; Tzy-Jyun Yao; Andrew D Seidman
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):275-9.
1999: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly; John Crown; A Surbone; M Uhlenhopp; Elyn Riedel; Tzy-Jyun Yao; Larry Norton
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1998: Andrew D Seidman; Clifford Hudis; J Albanell; J Albanel; William Tong; I Tepler; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; Marc J Gollub; José Baselga; Larry Norton
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3353-61.
1998: Clifford Hudis
Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):16-8.
1998: Clifford Hudis; L Riccio; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; David Lebwohl; Mary Ellen Moynahan; G Raptis; A Surbone; Nancy T Sklarin; Tzy-Jyun Yao; Deborah Keefe; Larry Norton
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1997: Clifford Hudis; L Riccio; F Holmes; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; M Uhlenhopp; N Maickel; Tzy-Jyun Yao; S Hellmann; J Usakewicz; Gabriel N Hortobagyi; Larry Norton
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Andrew D Seidman; Clifford Hudis; John McCaffrey; William Tong; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; I Tepler; Marc J Gollub; Larry Norton
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: Clifford Hudis; Patrick I Borgen
Systemic treatment for stage I and stage II breast cancer.
Surgical oncology clinics of North America 1997;6(4):683-98.
1997: Clifford Hudis
Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.
Oncology (Williston Park, N.Y.) 1997;11(4 Suppl 3):15-8.
1997: Andrew D Seidman; Clifford Hudis; G Raptis; José Baselga; DW Fennelly; Larry Norton
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):20-8.
1997: P M Hoff; Vicente Valero; Frankie A Holmes; H Whealin; Clifford Hudis; G N Hortobagyi
Paclitaxel-induced pancreatitis: a case report.
Journal of the National Cancer Institute 1997;89(1):91-3.
1996: Clifford Hudis; Larry Norton
Adjuvant drug therapy for operable breast cancer.
Seminars in oncology 1996;23(4):475-93.
1996: Clifford Hudis
Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):1971-3.
1996: Andrew D Seidman; Daniel Hochhauser; Marc J Gollub; B Edelman; Tzy-Jyun Yao; Clifford Hudis; P Francis; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; Violante E Currie; José Baselga; William Tong; M O'Donaghue; R Salvaggio; L Auguste; David Spriggs; Larry Norton
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1877-84.
1996: Clifford Hudis
New approaches to adjuvant chemotherapy for breast cancer.
Pharmacotherapy 1996;16(3 Pt 2):88S-93S.
1996: José Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I C Henderson; Larry Norton
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):737-44.
1996: Clifford Hudis; Andrew D Seidman; G Raptis; DW Fennelly; Teresa A Gilewski; José Baselga; Maria Theodoulou-Haber; Nancy T Sklarin; Mary Ellen Moynahan; A Surbone; Violante E Currie; David Lebwohl; M Uhlenhopp; John Crown; Larry Norton
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: Clifford Hudis; Andrew D Seidman; John Crown; Casilda Balmaceda; R Freilich; Teresa A Gilewski; T B Hakes; Violante E Currie; David Lebwohl; José Baselga; G Raptis; Marc J Gollub; M Robles; R Bruno; Larry Norton
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1995: J Crown; G Raptis; N Hamilton; Clifford Hudis; L Vahclat; DW Fennelly; Larry Norton
High-dose chemotherapy of breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():80-2.
1995: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Violante E Currie; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Seminars in oncology 1995;22(6 Suppl 15):18-23.
1995: Linda Vahdat; G Raptis; DW Fennelly; N Hamilton; Lilian Reich; A Tiersten; M Harrison; Clifford Hudis; Malcolm A S Moore; Tzy-Jyun Yao
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1267-73.
1995: Andrew D Seidman; A Tiersten; Clifford Hudis; Marc J Gollub; S Barrett; Tzy-Jyun Yao; J Lepore; Teresa A Gilewski; Violante E Currie; John Crown
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2575-81.
1995: Andrew D Seidman; Clifford Hudis; DW Fennelly; G Raptis; José Baselga; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Seminars in oncology 1995;22(5 Suppl 12):108-16.
1995: T A DiLorenzo; Paul B Jacobsen; Dana H Bovbjerg; H Chang; Clifford Hudis; Nancy T Sklarin; Larry Norton
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):705-11.
1995: Andrew D Seidman; Clifford Hudis; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seminars in oncology 1995;22(4 Suppl 8):3-8.
1995: Andrew D Seidman; B S Reichman; John Crown; Tzy-Jyun Yao; Violante E Currie; T B Hakes; Clifford Hudis; Teresa A Gilewski; José Baselga; P Forsythe
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1152-9.
1995: Paul B Jacobsen; Dana H Bovbjerg; M D Schwartz; Clifford Hudis; Teresa A Gilewski; Larry Norton
Conditioned emotional distress in women receiving chemotherapy for breast cancer.
Journal of consulting and clinical psychology 1995;63(1):108-14.
1994: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; Clifford Hudis; A Surbone
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: Clifford Hudis
Is there an alternative to alternating adjuvant therapy for breast cancer?
Cancer investigation 1994;12(3):329-35.
1994: Clifford Hudis
Do we need a "stopping rule" for breast cancer?
Cancer investigation 1994;12(5):543-4.
1993: John Crown; Linda Vahdat; DW Fennelly; P Francis; C Wasserheit; Clifford Hudis; A Kritz; J Schneider; N Hamilton; Teresa A Gilewski
High-intensity chemotherapy with hematopoietic support in breast cancer.
Annals of the New York Academy of Sciences 1993;698():378-88.
1993: Clifford Hudis; Larry Norton
Systemic adjuvant therapy for breast cancer.
Current opinion in oncology 1993;5(6):982-90.
1993: B S Reichman; Andrew D Seidman; John Crown; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Clifford Hudis
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1943-51.
1993: John Crown; A Kritz; Linda Vahdat; Lilian Reich; Malcolm A S Moore; N Hamilton; J Schneider; M Harrison; Teresa A Gilewski; Clifford Hudis
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1144-9.
1993: John Crown; T Hakes; B Reichman; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Tzy-Jyun Yao; Clifford Hudis; Andrew D Seidman
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Cancer 1993;71(4):1254-7.
1992: Dana H Bovbjerg; William H Redd; Paul B Jacobsen; Sharon Manne; Kathryn L Taylor; A Surbone; John Crown; Larry Norton; Teresa A Gilewski; Clifford Hudis
An experimental analysis of classically conditioned nausea during cancer chemotherapy.
Psychosomatic medicine 1992;54(6):623-37.
1992: Clifford Hudis; David P Kelsen
Menogaril in the treatment of malignant mesothelioma: a phase II study.
Investigational new drugs 1992;10(2):103-6.
1991: David P Kelsen; Clifford Hudis; D Niedzwiecki; J Dougherty; E Casper; J Botet; V Vinciguerra; R Rosenbluth
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Cancer 1991;68(5):965-9.
1987: Clifford Hudis
Expanding medical horizons: an overseas rotation.
American College of Physicians observer 1987;7(4):18.